Format
Sort by

Send to:

Choose Destination

Results: 4

1.

Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels.

McCormack K, Santos S, Chapman ML, Krafte DS, Marron BE, West CW, Krambis MJ, Antonio BM, Zellmer SG, Printzenhoff D, Padilla KM, Lin Z, Wagoner PK, Swain NA, Stupple PA, de Groot M, Butt RP, Castle NA.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):E2724-32. doi: 10.1073/pnas.1220844110. Epub 2013 Jul 1.

2.

N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.

Amato G, Roeloffs R, Rigdon GC, Antonio B, Mersch T, McNaughton-Smith G, Wickenden AD, Fritch P, Suto MJ.

ACS Med Chem Lett. 2011 Mar 31;2(6):481-4. doi: 10.1021/ml200053x. eCollection 2011 Jun 9.

3.

Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis.

Hetherington S, Texter M, Wenzel E, Patti JM, Reynolds L, Shamp T, Swan S.

Antimicrob Agents Chemother. 2006 Oct;50(10):3499-500.

4.

Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells.

Wickenden AD, Zou A, Wagoner PK, Jegla T.

Br J Pharmacol. 2001 Jan;132(2):381-4.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk